at Google ScholarTitle data
Hader, Michael ; Savcigil, Deniz Pinar ; Rosin, Andreas ; Ponfick, Philipp ; Gekle, Stephan ; Wadepohl, Martin ; Bekeschus, Sander ; Fietkau, Rainer ; Frey, Benjamin ; Schlücker, Eberhard ; Gaipl, Udo S.:
Differences of the Immune Phenotype of Breast Cancer Cells after Ex Vivo Hyperthermia by Warm-Water or Microwave Radiation in a Closed-Loop System Alone or in Combination with Radiotherapy.
In: Cancers.
Vol. 12
(2020)
Issue 5
.
- 1082.
ISSN 2072-6694
DOI: https://doi.org/10.3390/cancers12051082
Project information
| Project title: |
Project's official title Project's id Multiskalenuntersuchung der Hyperthermie für neue additive Tumorbehandlungsstrategien – Microthermia No information |
|---|---|
| Project financing: |
Bayerische Forschungsstiftung |
Abstract in another language
The treatment of breast cancer by radiotherapy can be complemented by hyperthermia. Little is known about how the immune phenotype of tumor cells is changed thereby, also in terms of a dependence on the heating method. We developed a sterile closed-loop system, using either a warm-water bath or a microwave at 2.45 GHz to examine the impact of ex vivo hyperthermia on cell death, the release of HSP70, and the expression of immune checkpoint molecules (ICMs) on MCF-7 and MDA-MB-231 breast cancer cells by multicolor flow cytometry and ELISA. Heating was performed between 39 and 44 °C. Numerical process simulations identified temperature distributions. Additionally, irradiation with 2 × 5 Gy or 5 × 2 Gy was applied. We observed a release of HSP70 after hyperthermia at all examined temperatures and independently of the heating method, but microwave heating was more effective in cell killing, and microwave heating with and without radiotherapy increased subsequent HSP70 concentrations. Adding hyperthermia to radiotherapy, dynamically or individually, affected the expression of the ICM PD-L1, PD-L2, HVEM, ICOS-L, CD137-L, OX40-L, CD27-L, and EGFR on breast cancer cells. Well-characterized pre-clinical heating systems are mandatory to screen the immune phenotype of tumor cells in clinically relevant settings to define immune matrices for therapy adaption.